R4 BluePrint

Strategic Consulting Service

Discovery Innovations’ core team and management have over 20 years of experience overseeing development, implementation, and commercialization of in silico informatics solutions across global pharmaceutical organizations at over 35 discovery research sites at Abbott, Aventis, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Roche, and Schering.

Discovery Innovations’ experience in the development and application of in silico solutions in the areas of target validation, genomics, proteomics, lead generation, lead optimization, library design, library production, library evaluation, and clinical research provide us with a broad perspective and comprehension of the strategies, systems, technologies, and user requirements employed to design and implement a successful discovery informatics platform.

We possess an ability to negotiate complex global R&D organizations, quickly identify critical issues and gaps in informatics strategies, develop and recommend alternative scenarios, and deliver a strategy document that serves as a collective blueprint for current and future development throughout the organization.

R4 BluePrint Methodology: